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Abstract
The Effects of Genistein, Thymoquinone, Epigallocatechin-3-gallate, 5-Fluorouracil, and
Low Level Laser Therapy on FaDu Hypopharyngeal and Laryngeal Carcinoma Cells
Osasu Noel Adah
Laryngeal and hypopharyngeal carcinoma are two types of head and neck
squamous cell carcinomas. The location of the tumor makes it hard to detect without
complex tests. Overall, these types of cancer are not common, and there are no simple
screening tests for such cancers. Due to this issue, laryngeal and hypopharyngeal
carcinoma are usually diagnosed when signs and symptoms occur, such as sore throat,
trouble swallowing, and constant coughing. With the use of FaDu, a head and neck
cancer cell line of the hypopharyngeal origin, experimentation can be performed in order
to initiate possible treatments. The standard treatments for laryngeal and hypopharyngeal
carcinoma include conventional chemotherapy, such as 5-fluorouracil and cisplatin,
chemo- radiation, and surgery. The treatments used in this experiment include 5Fluorouracil (5-FU), Genistein (G), Thymoquinone (TQ), Epigallocatechin-3-gallate
(EGCG), and low level laser therapy (LLLT). 5-FU is one of the most commonly used
drugs to treat several cancers, including head and neck cancers. G is an isoflavone
metabolite of soy generated by gut floral bacteria and has been characterized as a possible
prevention for cancer. TQ is an ingredient isolated from Nigella sativa and has been
investigated for its anti-oxidant, anti-inflammatory, and anticancer activities in both in
vitro and in vivo models. EGCG, one of the main flavonoids found in green tea, is
considered as one of the most active molecules known for its anti-oxidant properties.
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LLLT may enhance or decrease cell proliferation. LLLT has shown to induce apoptosis
in cancer such as a human colon carcinoma cell line by increasing reactive oxygen
species (Saenko et al 2016).
The goals of this experiment were to investigate the effects of LLLT on FaDu
cells and to determine the effects of natural products such as G, TQ, and EGCG, as
chemotherapeutic agents, and 5-FU (a conventional chemotherapeutic agent), combined
with LLLT, on FaDu cells. Specifically, cells were treated with LLLT, TQ, G, EGCG, or
5-FU; or LLLT plus TQ, G, EGCG, or 5-FU. The cells were then harvested and cellular
protein, intracellular glutathione levels, nitric oxide levels, and lactate dehydrogenase
levels were evaluated. Due to the low level of anti-cancer efficacy, G was discontinued.
The results show a significant decrease in protein levels and cell numbers following
treatment with TQ, however, this trend was inconsistent throughout the study. There was
a significant increase in nitric oxide and LDH levels following treatment with EGCG and
EGCG + laser, and this trend remained consistent throughout the study. However, since
EGCG displayed similar results as EGCG + laser, LLLT possibly does not have any
additional effect when combined to EGCG. Overall, LLLT did not show significant
effect on FaDu cells. EGCG alone was shown to be the most effective treatment, in
terms of inducing the most cellular damage and toxicity in the cancer cells.
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Introduction
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Laryngeal carcinoma (cancer of the larynx) is the 2 nd most common cancer in the
region involving the head and neck and is actually one of the more usual malignancies
worldwide in men (Binshen et al 2011). Hypopharyngeal carcinoma is also a head and
neck carcinoma that represents about 7% of all cancers of the upper aerodigestive tract.
The prevalence of laryngeal carcinoma is 4-5 times that of hypopharyngeal carcinoma
(Quon, 2015). According to the National Institute of Cancer in 2016, there were an
estimated 13,430 new cases and 3,620 deaths for laryngeal carcinoma. In contrast, an
estimated 3,400 adults in the United States will be diagnosed with hypopharyngeal cancer
according to the American Cancer Society (2016). The non-specific nature of nasal and
aural symptoms increases the likelihood to misdiagnose and leads to laryngeal and
hypopharyngeal carcinoma diagnoses at advanced stages (stages III-IV). Some of the
symptoms of both of these cancers include hoarseness in voice, persistent coughing,
difficulty swallowing, and ear pain. Treatment modalities often fail and are accompanied
by short and long term side effects of the chemotherapeutic drug, 5-Fluorouracil (5-FU).
Some of the side effects include neutropenia, anemia, tumor lysis syndrome, infertility,
and less commonly, angina and heart failure (Cancer Research UK, 2016). The use of
natural compounds, such as Genistein (G), Thymoquinone (TQ), and Epigallocatechin-3gallate (EGCG), which stop cancer in different phases of the cell cycle, may provide an
alternative to 5-FU drug regime due to possible less hazardous side effects and greater
efficacy.
In order to study laryngeal and hypopharyngeal carcinoma, we used a head and
neck cancer cell line known as FaDu. This cell line is specifically a hypopharyngeal
carcinoma, however, it is sufficient to use in the investigation of laryngeal carcinoma due
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to the closeness in structures, similar possible causes, signs, symptoms, and treatments.
According to the ATCC, the FaDu line was established from a biopsy of a
hypopharyngeal tumor removed from a patient in 1968. With the use of FaDu,
experimentation can be performed in order to initiate possible treatments.
Anti-metabolites have been used to treat different types of cancers. Fluorouracil
(5-FU) belongs to this class of chemotherapy drugs that is specifically a pyrimidine
antimetabolite that usually acts on cells in the G1 to S phases of the cell cycle (Tohru et
al 2013). 5-FU works by being incorporated into DNA and RNA replicating cycles and
preventing further cell growth. The G1 (Gap 1) phase of the cell cycle is where the size
of the cells increase and are being prepared for DNA replication. The S phase of the cell
cycle is where DNA replication/synthesis occurs. According to results associated with
combination chemotherapy with the DNA damaging cisplatin (CDDP) and 5-FU for
laryngeal carcinoma, it is verified that CDDP and 5-Fu, along with radiotherapy,
contributed to laryngeal preservation. The irreversible side effects of using CDDP and 5FU include peripheral neuropathy and nephrotoxicity. The reversible side effects of
using CDDP and 5-FU with chemotherapy include leukopenia, neutropenia, mucositis,
and dermatitis (Furusaka et al 2013).
The use of isoflavones as a plausible treatment for laryngeal carcinoma has been
investigated due to their cytostatic and cytotoxic effects on the body. Genistein (G) is
one of the main soy isoflavones. G has been described to be a protein kinase inhibitor,
which can block proliferation of squamous cell carcinoma and also arrest cell growth,
especially at the S/G2-M phase of the cell cycle (Alhasan et at 1999). The G2 (Gap 2)
phase of the cell cycle is where the cell is still growing and is getting prepared to divide.
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Cell cycle arrest at the G2/M phase of the cell cycle was also shown when human
intestinal colon cancer cells (Han et al, 2013) and human oral squamous carcinoma cells
(Ye et al 2004) were treated with G. This isoflavone initiates programmed cell death
(apoptosis) in the malignant cells (Alhasan et al 1999). Because of the absence of toxic
effects and the natural biological influences of flavonoids in general, a diet rich in
isoflavonoids, including genistein, can play a major part in the prevention of cancer
(Alhasan et al, 1999).
TQ is a component isolated from Nigella sativa and has been considered for its
anti-cancer activities in both in vitro and in vivo models since its first extraction in 1960s.
Its anti-oxidant and anti-inflammatory effects have been reported in various disease
models, including encephalomyelitis, diabetes, asthma, and carcinogenesis (Woo et al,
2011). TQ has also been found to induce cell death in human oral squamous carcinoma
cells by caspase-activation dependent apoptosis (Chu et al, 2014). Caspase is a type of
protease. The activation of this enzyme ensures that the cellular components are degraded
in a controlled manner, which allows for apoptosis to take place with minimal effect to
surrounding tissues (Rathore et al, 2015). TQ induces apoptosis in p53-dependent or
p53-independent pathways in 6 human colorectal carcinoma cells. TQ arrests cell cycle
progression in different types of tumor cells, specifically inducing G0/G1 arrest possibly
through the increase in the expression of p16 and decrease in cyclin D1 in mouse
papilloma carcinoma cells and other kinds of cancer, including acute lymphoblastic
leukemia and prostate cancer cells (Hala et al 2004). Studies have also shown that TQ
induces G2/M arrest in other cancer cells, including MNNG/HOS human osteosarcoma
cells and MCF-7/DOX doxorubicin-resistant breast cancer cells (Woo et al 2011).
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The anti-cancer effects of TQ are mediated through different modes of action:
anti-proliferation, apoptosis induction, cell cycle arrest, ROS (Reactive Oxygen Species)
generation, and anti-metastasis/anti-angiogenesis. TQ modulates multiple molecular
targets, including p53, p73, PTEN, and STAT3. There are two mechanisms that might
contribute to growth inhibitory activities of TQ in vitro: apoptotic cell death and
interference with the cell cycle due to increased cyclin-dependent kinases and negative
regulator involved in G1 cell cycle control (Shoeib et al 2003). In vivo studies have
demonstrated that TQ decreases CDDP-induced side effects, including nephrotoxicity,
without compromising its antitumor activity (Shoeib et al 2003).
EGCG is a flavonoid found in green tea and is known for its antioxidant
properties (Legeay et al 2015). EGCG causes cell cycle arrest in the G1 phase in oral
squamous cell carcinoma cells by upregulating B-cell translocation gene 2, which is a
regulatory protein of the cell cycle (Lee et al 2015). Studies have also shown that EGCG
inhibits the self-renewal capacity of head and neck squamous carcinoma cancer stem
cells by suppressing their sphere-forming capacity, which is a measure of tumorigenicity
(Lee et al 2013). EGCG inhibits enzyme activities, such as NFĸB, in head and neck
carcinoma cells, which result in suppression of cell proliferation, enhancement of
apoptosis, and inhibition of cell invasion, angiogenesis, and metastasis (Chung et al
2012). NFĸB is known for its role in inflammation, and EGCG blocks this enzyme from
being activated (Zhe et al, 2004). Overall, EGCG seems to be one of the most promising
naturally-derived compounds that demonstrate tumor suppressive effects on animal
carcinogenesis models, mouse xenograft models, and several cancer cell lines (Muneyuki
et al 2011).
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Low level laser therapy (LLLT) involves exposing cells or tissue to low levels of
red and near infrared (NIR) light, and is referred to as “low level” because of its use of
light at energy densities that are low as compared to other forms of laser therapy that are
used for ablation, cutting, and thermally coagulating tissue (Hamblin, 2008). From
observation, it appears that LLLT has a wide range of effects at the molecular, cellular,
and tissue levels. There are three major roles that LLLT is typically used for: wound
healing, tissue repair, and inflammation relief (Hamblin, 2008). LLLT has been used
clinically by physical therapists to treat a variety of musculoskeletal aches and pains, by
dentists to treat inflamed oral tissues and to heal ulcerations, by dermatologists to treat
edema, ulcers, burns, and dermatitis, by orthopedists to relieve pain and treat chronic
inflammation and autoimmune diseases, and more (Hamblin, 2008). Within the cell, there
is strong evidence to suggest that LLLT acts on the mitochondria to increase adenosine
triphosphate (ATP) production, modulating reactive oxygen species (ROS). LLLT has
shown promise for down regulating inflammation by reducing the presence of reactive
oxygen species (ROS). However, there are limited studies on how LLLT affects cancer
cells. Studies involving laser treatment on bone tumors have shown that a wavelength of
830nm increased osteoblast proliferation significantly and reduced osteosarcoma cells at
an energy level of 10 J/cm2 (Renno et al 2007). LLLT has limited systemic effects and
may be implicated in toxic reduction in the body (Rhee et al 2012).

Goals, Hypotheses, and Specific Aims
In the literature, studies that tested the dual effects of LLLT and anti-cancer
agents such as 5-FU, G, TQ, and EGCG are limited. Therefore, the goals of this study
6

were to 1) determine the effects of LLLT on FaDu cancer cells and to 2) determine the
effects of natural products or a conventional chemotherapeutic agent, 5-FU, in
combination with LLLT on cancer cell growth.
Hypothesis I: FaDu cancer cells exposed to laser treatments will show a reduction
in cell number and viability.
Specific Aim: To determine the effect of 830 nm of laser light on FaDu cells, protein
levels were measured as a correlate to cell number, and cell function was monitored via
glutathione levels at 24, 48, and 72 hours post LLLT. LLLT effects were compared to 5FU, G, EGCG, and TQ at their pre-determined, respective time-dependent IC50’s.
Hypothesis II: FaDu cancer cells exposed to laser treatment in combination with
single-dose cell cycle specific drugs/compounds will show a greater reduction in cell
numbers than compared to the administration of separate treatments.
Specific Aim: To determine the effect of 830 nm of laser light on FaDu cells, cell
function, and after 24, 48, and 72 hours in combination with chemotherapeutic drugs (5FU) and other natural products at their time-dependent IC50’s.
Hypothesis III: Treatment cell cycle specific drugs/compounds and additional
treatment of LLLT will show a greater eradication or suppression cancer cell
growth compared to single-dose treatment of LLLT.
Specific Aim: To determine the effects of additional treatment with 830 nm laser light in
combination with chemotherapeutic drug (5-FU) and other compounds (TQ and EGCG)
on FaDu cell numbers and cell function after 24, 48, and 72 hours.
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Background of LLLT and treatment in study:
In phase 1, the cells were treated with each of the treatments (TQ, EGCG, and 5FU). The cells were then placed in the incubator for 30 minutes. Next, the laser
treatment was added to the designated cells. The cells were then harvested at 24, 48, and
72 hours. In phase 2, the cells were treated with each of the treatments (TQ, EGCG, and
5-FU). The cells were then placed in the incubator for 30 minutes. Next, laser treatment
was added to the designated cells that were to be harvest at 24, 48, and 72 hours. The
same day that the 24-hour cells were being harvested, laser treatment was done again for
the 48 and 72-hour cells. The same day that the 48-hour cells were being harvested, laser
treatment was done the third time for the 72-hour cells. The next day, the 72-hour cells
were harvested.
The laser (830 nm) used in this study has three diodes on the face. The mean
power of each diode is 30mW and the pulse duration lasts for 33 seconds. Therefore, a
total of about 3 Joules of energy is emitted from the diodes and the duration lasts for 33
seconds. A total of 10 Joules is needed for this present study; therefore, the laser duration
cycle was repeated once. Next, one of the diodes was covered to give a total 2 Joules,
and then repeated once. Therefore, the total duration that the laser was treating the cells
was about 132 seconds. Figure 1 shows a diagram of the laser used in the study.
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Figure 1: Diagram of Low Level Laser (Microlight ML830)
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Overview of Laryngeal Carcinoma
Laryngeal carcinoma (head and neck squamous cell carcinoma) is a malignancy
that represents about 2-5% of cancers, but represents about 85-90% of squamous cell
carcinomas (Wolf 2016). Symptoms of laryngeal and hypopharyngeal carcinoma include
voice changes (hoarseness), constant sore throat, coughing, trouble or pain while
swallowing, earache, trouble breathing, weight loss, and mass in neck (American Cancer
Society, 2015). The exact etiological factors for laryngeal and hypopharyngeal
carcinoma are unknown, but many co-factors, including tobacco smoking, alcohol
consumption, poor diet, and depressed immune system, have presumed contributions
(Mastronikolis et al 2012).
The 5-year survival rate for laryngeal carcinoma depends on the location of the
cancer—glottis, supraglottis, or subglottis. Cancer in the glottis region, part of the larynx
that include the vocal cords, has a 5-year survival rate of 90% for stage I, 74% for stage
II, 56% for stage III, and 44% for stage IV. Cancer in the supraglottic region, part of the
larynx that is above the vocal cords, has a 5-year survival rate of 59% for stage I, 59% for
stage II, 53% for stage III, and 34% for stage IV. Cancer is the subglottic region, part of
the larynx below the vocal cords, has 5-year survival rate of 65% for stage I, 56% for
stage II, 47% for stage III, and 32% for stage IV. The 5-year survival rate for
hypopharyngeal carcinoma (area around vocal cords) is 53% for stage I, 39% for stage II,
36% for stage III, and 24% for stage IV (American Cancer Society, 2016). Laryngeal
and hypopharyngeal carcinoma are staged according to the Tumor-Node-Metastasis
(TNM) classification system (stages 0-IV). This system takes into account the size and
location of the tumor (T), lymph node involvement (N), and presence of distant
metastasis (M) (Mastronikolis et al 2012). There are five stages of laryngeal carcinoma.
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In Stage 0, the cancer cells are only growing in the inner lining layer of the larynx; there
is no evidence the cancer has spread to the lymph nodes or beyond. In Stage I, the tumor
is only in the vocal cords; there is no evidence the cancer has spread to the lymph nodes
or beyond. In Stage II, the tumor is growing into the supraglottis/subglottis and/or the
vocal cords do not move normally, but there is no evidence of lymph node involvement
or distant metastasis. In Stage III, the tumor is in the larynx with vocal cord paralysis.
The tumor could also be growing into the paraglottic space or into the inner part of the
thyroid cartilage. Notably in stage III, the cancer is likely to have spread to a single
lymph node on the same side of the neck as the tumor, and the node is < 3 cm across. It is
possible that there is no evidence the cancer has spread to the lymph nodes, and it has not
spread to distant sites. In Stage IV, either the tumor has grown through the thyroid
cartilage and/or is growing into tissues beyond the larynx, or the tumor is growing into
the tissue anterior to the spine in the neck (the prevertebral space), surrounds a carotid
artery, or is growing down into the space between the lungs. The cancer could possibly
spread to at least 1 lymph node that is larger than 6 cm across and possibly spread to
distant sites (American Cancer Society, 2015). Survival decreases by more than one
third when clinically positive lymph nodes are present. There is a five-year disease free
survival of patients with supraglottic cancer is 80% for stages I-II, 70% for stage III and
40% for stage IV. Patients with glottic cancers have a better long-term prognosis. There
is a five-year disease free for stages I-II is 85%-90%, for stage III is 75% and for stage IV
is 45%-50%. However, in cases with an extremely advanced local and regional disease
the overall 5-year survival is less than 5% (Mastronikolis et al 2012). There are also five
stages for hypopharyngeal carcinoma. In stage 0, there is no evidence of primary tumor,
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or any regional lymph node or distant metastasis. In stage I, the tumor is limited to one
subsite of the hypopharynx, and there is no regional lymph node or distant metastasis. In
stage III, the tumor is either greater than 4 cm in dimension from extension to the
esophagus. The tumor could possibly be limited to 1 subsite of the hypopharynx and/or
≤2cm in greatest dimension or invade more than 1 subsite. Metastasis could be in a
single lymph node ≤3 cm in greatest dimension and/or no distant metastasis. In stage IV,
the tumor could invade the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central
compartment soft tissue and could range from having no regional lymph node metastasis
to metastasis in a lymph node >6cm in greatest dimension. Distant metastasis is also a
possibility (Stevenson, 2016). The larynx and pharynx are illustrated in figure 2.

Figure 2: Illustration of the larynx and pharynx showing labeled parts

Cellular changes in Laryngeal and Hypopharyngeal Carcinoma:
Common cellular changes that occur in laryngeal and hypopharyngeal
carcinogenesis include those involving, the tumor suppressor p53, the proto-oncogene
cyclin D1, and tumor suppressor p16 (Williams et al, 2015; Fu et al, 2007). p53 is a
13

nuclear phosphoprotein and tumor protein involved in gene transcription, apoptosis, DNA
repair and synthesis, and cell cycle regulation (Mastronikolis, 2012). p53 is the
gatekeeper of DNA integrity at the R checkpoint of the cell cycle. This protein is mutated
in more than 50% of human tumors. p53 point mutations, deletions, and inactivation
occur in the shift from the pre-invasive to the invasive state of laryngeal carcinoma
(Mastronikolis, 2012). Mutations include loss of G1/S checkpoint control and the
inability for apoptosis to regularly occur. The inactivation of p16 and p53 occur early in
the development and progression of laryngeal carcinoma (Williams et al, 2015). Cyclin
D1 is involved in cell cycle progression and interacts with cyclin-dependent kinases.
When cyclin D1 gene amplification is observed in precancerous and cancerous lesions, it
is always overexpressed. In this state of increased expression, cyclin D1 drives more
cells into the G2/M phase of the cell cycle (Mastronikolis et al., 2012).

Standard of treatment of laryngeal and hypopharyngeal carcinoma by stage:
In stage 0 for laryngeal carcinoma, the cancer is usually in the glottic area. Vocal
cord stripping, laser surgery, or radiation therapy are mainly used as treatment options In
stage I and II of laryngeal carcinoma, either radiation without surgery or partial
laryngectomy usually takes place. Particularly, glottis cancers are usually treated by
removing the vocal cords. Supraglottic cancers, the lymph nodes are usually removed.
In stage III and IV of laryngeal carcinoma, treatment is usually some combination of
surgery, radiation, and/or chemotherapy. Initial treatment usually includes surgery or
chemotherapy (common chemotherapeutic drugs include cisplatin and 5-FU) with
radiation. In stage I for hypopharyngeal carcinoma, surgery and/or radiation are usually
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the main options for initial treatment. Surgery usually includes removing all or part of
the pharynx along with the lymph nodes on the sides of the neck. In stages II, III, IV for
hypopharyngeal carcinoma, the first option is usually to remove the pharynx, larynx, and
lymph nodes in neck area, accompanied by radiation or radiation with chemotherapy.
Treatment first with chemotherapeutic drug, such as cisplatin, along with radiation, is
another option (American Cancer Society, 2016).
Tables 1-5 below display different studies involving the treatments and their findings.

Table 1: Studies on the Effect of Genistein
Year
1999

Author(s)
Alhasan et al

2010

Tokkalov et al

2010

Johnson et al

2013

Han et al

Cell Line/Type
HN4 squamous
cell carcinoma
cell line

Major Findings
--genistein inhibits proliferation of a
squamous cell carcinoma cell line
--caused cell cycle arrest at the S/G2-M
phase and induced apoptosis
-- shown to inhibit cell proliferation
and to induce cell cycle arrest at the
G2-M phase in breast, prostate, and
jurkat T cell leukemia cell lines.
p53-deficient cells --genistein-based therapy may have
(H1299, FaDu)
antagonistic effects when combined
with mitotic poisons.
--proposed therapeutic strategy allows
protection of p53 wild type cells from
taxol and selectively increases
apoptosis in p53-deficient cells.
SCC15 and
--genistein inhibited SCC15 and
SCC25 squamous SCC25 cell growth.
cell carcinoma
--induced a decrease in
cell lines
phosphorylation of ERK and Akt at
treatment concentrations of 20, 50 and
100 μM.
(Akt accelerates tumor progression)
human intestinal
--genistein significantly suppressed cell
colon cancer
proliferation.
Caco-2 cells
--demonstrated to modulate cell cycle
distribution through accumulation of
cells at G2/M phase, with a significant
decreasing effect of Cyclin B1 and
15

2013

Zheng et al

SK-N-SH human
neuroblastoma
cells

2013

Hara et al

participants with
gastric cancer

2011

Ayhen et al

nasopharyngeal
carcinoma cell
line CNE

2004

Ye et al

2001

Akimoto et al

2000

Alhasan et al

2012

Li et al

Serine/threonine-protein kinase 2
(Chk2) proteins expression
-- Cells were arrested at the G2/M
phase by genistein
-- estradiol- or environmental
endocrine disruptor-induced
proliferation of human neuroblastoma
cells is effectively abolished by
genistein, likely in a cell cycle- and Akt
pathway-dependent manner
-- no association of plasma isoflavone
concentrations with gastric cancer risk

-- genistein induced a G2/ M cell cycle
arrest
--induces nasopharyngeal cancer cell
early apoptosis rate
-- characteristic morphological changes
of apoptosis in CNE cells was observed
after treated by genistein
human oral
-- genistein inhibited SCC-25 cell
squamous
growth via G2/M phase arrest.
carcinoma line
-- significant decrease of proliferating
(SCC-25)
cell nuclear antigen expression in these
cells after treatment
human esophageal -- Genistein (30 microM) greatly
squamous cell
enhanced radiosensitivity in cell lines
cancer cell lines,
by suppressing radiation-induced
TE-1 (p53,
activation of survival signals, p42/p44
mutant) and TE-2 extracellular signal-regulated kinase
(p53, wild)
and AKT/PKB
HN4 squamous
-- down-regulation of Cdk1, and
cell carcinoma of CyclinB1, and up-regulation of the
the head and neck cyclin dependent kinase (Cdk) inhibitor
cell line (HNSCC) p21WAF1--may be responsible for the
induction of cell cycle arrest and
apoptosis
Neuroblastoma
--genistein, is an epigenetic modifier
(NB) cell line
able to decrease hypermethylation
levels of CHD5, and enhances the
expression of CHD5 as well as p53
(tumor suppressor genes), which may
contribute to inhibition of NB growth
in vivo and tumor micro-vessel
formation
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Table 2: Studies on the Effect of Thymoquinone

Year
2012

Author(s)
Woo et al

Cell Line/Type
Review: tumor
xenograft mice
models for colon,
prostate, pancreatic
and lung cancer
human
osteosarcoma cells

2007

Roepke et al

2010

Gurung et al

Glioblastoma cells

2003

Shoieb et al

2012

Lei et al

canine
osteosarcoma
(COS31), human
breast
adenocarcinoma
(MCF7), human
ovarian
adenocarcinoma
(BG-1) and MadinDarby canine
(MDCK) cell lines
gastric cancer cells
xenograft tumor
mouse model

2015

Wilson et al

Major Findings
--review: anti-oxidant/antiinflammatory and anticancer effects
of TQ with a focus on its molecular
targets,
-- TQ induces p53-independent
apoptosis in human osteosarcoma
cells
-- TQ induces DNA damage,
telomere attrition by inhibiting
telomerase and cell death in
glioblastoma cells
--TQ induced apoptosis of COS31
and decreased the number of COS31
cells in S-phase and increased cells in
G1-phase, indicating cell cycle arrest
at G1

-- pretreatment with TQ significantly
increased the apoptotic effects
induced by 5-FU in gastric cancer cell
lines in vitro
-- TQ enhanced the 5-FU-induced
killing of gastric cancer cells by
mediating the downregulation of the
anti-apoptotic protein bcl-2, the
upregulation of the pro-apoptotic
protein bax, and the activation of both
caspase-3 and caspase-9
ID8-NGL mouse
-- TQ reduced proliferation and
ovarian cancer cells increased apoptosis in ID8-NGL
tumors after 10 and 30 day treatment
-- Prolonged TQ treatment did not
significantly alter tumor number or
mass compared to vehicle, but
exerted an overall deleterious effect
by stimulating ascites formation
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2015

Parbin et al

MCF-7
breast cancer cells

2015

Harpole et al

SK-OV-3
Ovarian Cancer

2015

Dehghani et al

human breast
adenocarcinoma
cell line (MCF7)
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-- TQ elicited downstream effects of
induction of the pro-apoptotic gene
Bax, down regulation of the antiapoptotic gene Bcl-2 and arrest of the
cell cycle at the G2/M phase.
--the result of a higher cytotoxicity of
TQ towards MCF-7
breast cancer cells in comparison to
normal cells indicates the potential of
TQ to be an anticancer drug
-- increase in nitric oxide following
the administration of EGCG alone
and in combination with TQ
compared with TQ alone or untreated
control cells with the difference being
about three-fold higher
-- Proliferation of MCF7 cells was
significantly inhibited by TQ and
nanothymoquinone in a
concentration-dependent manner in
defined times

Table 3: Studies on the Effect of 5-Fluorouracil
Year
2013

Author(s)
Ghiringhelli et al

Cell Line/Type
myeloidderived
suppressor cells

2013

Zhang et al

Colorectal
cancer

2013

De la Cueva et al

2012

Chen et al

Colorectal
cancer-tumor
derived cell
lines/mouse
xenograft
models
Hep-2/5-Fu Cell -- the drug resistance cell line had
line
slower growth rate and larger size
-- Hep-2/5-Fu cell line showed cross
drug resistance to 5-Fu, cisplatin and
vincristine

2013

Furusaka et al

Squamous cell
carcinoma of
the glottis
larynx

2011

Ma et al

FaDu cell line
and resistant
cell line,
FaDu/T
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Major Findings
-- 5FU-driven activation of the NLRP3
inflammasome in MDSCs promotes
tumor angiogenesis by eliciting TH17
responses that compromise anticancer
immunity
-- detection for G2194A, T85C and
T464A could predict ~13% of 5-FU
severe toxic side effects
-- both ChoKa and 5-Fu in
combination display a synergistic antitumor effect due to ChoKa inhibitorsdriven modulation of the
metabolization of 5-FU.

-- synergistic effects of anticancer
chemotherapy combined with
chemoradiation therapy for squamous
cell carcinoma caused marked cancer
tissue degeneration
-- Side effects included leukopenia,
neutropenia, mucositis, and dermatitis
-- multidrug resistant sensitivities of the
FaDu/T cells to cisplatin (DDP), 5-FU,
doxorubicin (Dox) and vincristine
(VCR) were investigated
-- percentages of FaDu/T cells in the
G0/G1 and G2/M phases were
increased while the cell percentage in
the S phase decreased as compared with
the percentages of FaDu cells. The antiapoptotic ability increased prominently,
as the index of apoptosis decreased

Table 4: Studies on the Effect of LLLT
Year

Author(s)

Model/Cell
Type
diabetic rats

Major Findings

2013

Firat et al

2013

Sperandio et al

cells (DOK) and
oral cancer cells
(SCC9 and
SCC25)

2009

Frigo et al

melanoma cells
(B16F10) in
mice

2014

Gomes et al

2003

Kreisler et al

tongue
squamous
carcinoma cell
line (SCC25)
human
periodontal
ligament
fibroblasts
(PDLF)

2002

Kreisler et al

human gingival
fibroblasts
(HGF) in vitro
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-- LLLT elicits a positive healing effect
on palatal mucoperiostal wounds, and
modulates the oxidative status
-- reduced numbers of inflammatory
cells, and increased mitotic activity of
fibroblasts, collagen synthesis, and
vascularization
-- LLLT (660 nm or 780 nm;2.05, 3.07
or 6.15 J/cm²) can modify oral
dysplastic cells (DOK) and oral cancer
cells (SCC9 and SCC25) growth by
modulating the Akt/mTOR/CyclinD1
signaling pathway;
--LLLT significantly modified the
expression of proteins related to
progression and invasion in all the cell
lines, and could aggravate oral cancer
cellular behavior
-- Irradiation should be avoided over
melanomas as the combination of high
irradiance (2.5 W/cm(2)) and high dose
(1050 J/cm(2)) significantly increases
melanoma tumor growth in vivo
-- LLLT exerts a stimulatory effect on
proliferation and invasion of SCC25
cells
-- 809-nm diode laser; 1.96-7.84 Jcm-2
-- irradiated cells revealed a
considerably higher proliferation
activity than the controls. The
differences were significant up to 72 h
after irradiation
-- 809-nm semiconductor laser; 1.967.84 J/cm(2)
-- irradiated cells revealed a
considerably higher proliferation
activity; differences were highly
significant 24 hour after irradiation but
decreased in an energy-dependent
manner after 48 and 72 hour after
irradiation

2010

Peplow et al

**review—
human and
animal cells in
culture

-- results consistently demonstrated the
potential of laser irradiation to affect
cellular proliferation in a wavelengthand dosage-dependent manner

2002

Pinheiro et al

Laryngeal
carcinoma cells- H.Ep.2 cells

2005

Werneck et al

HEP2 cells

2007

Renno et al

normal primary
osteoblast
(MC3T3) and
malignant
osteosarcoma
(MG63) cell
lines

2012

Rhee et al

Cochlear hair
cells

2016

Saenko et al

HCT-116 and
CHO-K cells
(human colon
carcinoma cell
line)

--670nm laser irradiation led to an
increased cell proliferation when
compared to both control and 635nm
irradiated cells
--best cell proliferation was found with
670nm laser irradiated cultures exposed
to doses of doses of 0.04 to 0.48 J/cm2
-- both dose and wavelength are factors
that may affect cell proliferation of
HEP2 cells
-- Time, treatment, and wavelength
significantly influenced the
proliferation process of HEP2 cells
--685 and 830 nm
-- Osteoblast proliferation increased
significantly after 830-nm laser
irradiation (at 10 J/cm(2)) but decreased
after 780-nm laser irradiation (at 1, 5,
and 10 J/cm(2))
-- Alkaline phosphatase (ALP) activity
in the osteoblast line was increased after
830-nm laser irradiation at 10 J/cm(2)
-- each cell line responds differently to
specific wavelength and dose
combinations
-- LLLT may promote hair cell survival
following gentamicin damage in the
cochlea
--Laser irradiation has induced a dosedependent cell death via increasing
intracellular reactive oxygen species
(ROS) concentration, increase of DNA
damage, decrease of mitochondrial
potential, and reduced glutathione.
--the increase of the intracellular ROS
concentration induced by mitochondrial
damage contributes to the damaging
effect of the laser irradiation at 1265 nm
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2016

Bartos et al

HEI-OC1
auditory cells

2015

Giuliani et al

Mouse
Embryonic
Fibroblast
(MEF)

2014

Agrawal et al

Multiple tissues

2016

Zhou et al

stress-induced
premature
senescence
(SIPS) model

2014

Mocan et al

pancreatic
cancer cells
(PANC-1)

2013

Huang et al

Mouse cortical
neuron
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--Near infrared photobiomodulation
therapy at 810 nm, 30 mW/cm2 , 100
seconds, 1.0 J, 3 J/cm2 changed
mitochondrial metabolism and
oxidative stress response for up to 24
hours post treatment.
--LLLT at 670 nm, when dispensed in
pulsed mode, modifies mitochondria
network dynamics, as well as
expression level of mRNA encoding for
selective matrix proteins in MEF
--LLLT has been used for nearly 50
years to enhance tissue healing and to
relieve pain, inflammation and swelling.
The photons are absorbed in
cytochrome(c) oxidase (unit four in the
mitochondrial respiratory chain), and
this enzyme activation increases
electron transport, respiration, oxygen
consumption and ATP production.
--5-aminolevulinic acid photodynamic
therapy (ALA-PDT) elicits oxidative
damage and apoptosis in photoaged
fibroblasts in vitro, which may be the
basis for the rejuvenating effects on
photoaged skin.
--multi-walled carbon nanotubes and
polyethylene glycol (PEG) laser
mediated treatment (808 nm, 2W) leads
to mitochondrial membrane
depolarization that activates the flux of
free radicals within the cell and the
oxidative state mediate cellular damage
in PC cells via apoptotic pathway.
--LLLT increases ROS in normal
neurons, it reduces ROS in oxidativelystressed neurons. In both cases
mitochondrial membrane potential is
increased

Table 5: Studies on the Effect of EGCG
Year
2015

Author(s)
Legeay et al

Cell Line/Type
**Review

2012

Min et al

**non-specific

2003

Gupta et al

human prostate
carcinoma cells

2015

Flores-Perez et al

A549 lung
cancer cells

2015

Irimie et al

SSC-4 human
oral squamous
cell carcinoma
(OSCC)

2015

Lee et al

2015

Liu et al

Oral squamous
cell carcinoma
(OSCC)
human
esophageal
squamous cell
carcinoma cell
lines, Eca-109
and Te-1
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Major Findings
-- EGCG modulates cellular and
molecular mechanisms of various
symptoms leading to metabolic
syndrome
-- preferential death of cancer cells by
EGCG could be caused by the cancerspecific induction of ROS and
epigenetic modulation of expression of
apoptosis-related genes, such as hTERT
-- EGCG causes an induction of G1
phase ckis, which inhibits the cyclincdk complexes operative in the G0/G1
phase of the cell cycle--causes an arrest,
leading to apoptotic cell death
-- abrogation of HDGF by EGCG
enhances cisplatin-induced apoptosis
and sensitize A549 cells to
chemotherapy
-- Cell death was associated to
increased apoptosis, disruption of the
mitochondrial membrane potential, and
activation of caspase-3 and caspase-9
-- EGCG treatment suppresses cell
proliferation of SSC-4 human oral
squamous cell carcinoma (OSCC),
(dose- and time-dependent)
--activation of apoptosis and autophagy
in response to EGCG exposure in SSC4 cells
-- EGCG attenuates cell proliferation of
OSCC cells by upregulating BTG2
expression via p38 and ERK pathways
--EGCG inhibits proliferation and
induces apoptosis through ROS
production, caspase-3 activation, and a
decrease in VEGF expression in vitro
and in vivo
-- Tumor cells were arrested in the G1
phase

2013

Lee et al

head and neck
squamous
carcinoma
(HNSC)

2009

Wang et al

Laryngeal
squamous cell
carcinoma
(LSCC) cell
line Hep-2

2010

Lee et al

2011

Muneyuki et al

human
laryngeal
epidermoid
carcinoma of
the larynx Hep2
cells
head and neck
squamous cell
carcinoma
(HNSCC)

2011

Joseph et al

squamous cell
carcinoma of
the head and
neck (SCCHN)

2009

Chung et al

**review
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-- EGCG inhibits the self-renewal
capacity of HNSC CSCs by
suppressing their sphere forming
capacity, and attenuates the expression
of stem cell markers, such as Oct4 and
Sox2
-- EGCG decreased the transcriptional
level of Notch, resulting in the
inhibition of Notch signalling
-- treatment of Hep-2 cells with EGCG
decreased the cell viability, inhibited
the growth and proliferation, induced
apoptosis and increased the activity of
caspase-3 in a dose-dependent manner
--EGCG-treatment repressed
telomerase activity effectively in a
concentration-dependent manner
-- p53-mediated mitochondrial pathway
and the nuclear translocation of AIF
and EndoG play a crucial role in
EGCG-induced apoptosis of human
laryngeal epidermoid carcinoma Hep2
cells
--EGCG has shown clinical efficacy
and unique biological effects on lipid
rafts that are an important platform of
numerous biophysical
functions including RTKs signalings.
-- EGCG modulates several key
molecular signaling pathways at
multiple levels and has synergistic or
additive effects when combined with
many other natural or synthetic
compounds (review)
--EGCG inhibit enzyme activities and
signal transduction pathways, resulting
in the suppression of cell proliferation
and enhancement of apoptosis, as well
as the inhibition of cell invasion,
angiogenesis and metastasis

Materials and Methods
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Cells and Culture: The FaDu cell is a squamous cell carcinoma originating from a
hypopharyngeal tumor removed from a patient in India (Wiley). For this experiment, the
FaDu cells were obtained from the American Type Culture Collection (ATCC, Rockville,
MD). The FaDu cell line was grown in 90% Eagle’s Minimum Essential Medium
(EMEM) with 10% fetal bovine serum (FBS). FaDu cells were cultured and plated in
either 24-well tissue culture plates at a density of 1.0 x 106 cells per well or in 6-well
tissue culture plates at 5 x 106 for the laser experiments since the area of the well
(9.5cm2) was comparable to the head of the laser. The cells were then incubated in a CO 2
(5% CO2 and 95% air) at 37˚C until treatment.
Treatment of Cells: For the first set of experiment in the 24 well plates, cells in the first
row were left untreated and served as the control and cells in rows 2-4 were treated with
IC50 doses of either Genistein (25 mM), TQ (16 µM ) and 5-FU (16 µM). For
experiments in 6 well plates involving LLLT, cells were treated with laser or IC 50 doses
of EGCG, TQ, and 5-FU, and placed in the incubator for 30 minutes prior to LLLT
treatment and then incubated for 24, 48, and 72-hour intervals. For LLLT, cells were
treated with 10 Joules (1.05 J/cm2) at 830 nm wavelength. (Genistein was replaced with
the IC50 dose of EGCG (3 µM)). Additional experiments were performed with daily
treatments of LLLT and followed for 24, 72, and 96 hours (change in harvest time was
used since the doubling time for these cells was found to be 48 hours) of treatment with
the chemotherapeutic agent 5-FU for 30 minutes followed by daily treatments with
LLLT. In the final experiments, the cells were treated and incubated for 30 minutes with
the IC50 doses with TQ, 5-FU, EGCG, followed daily laser therapy. In the first phase of
this set, the cells were treated for one day, then LLLT was performed for each day (24,
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48, and 72 hours). In the second phase, the cells were treated each day, 30 minutes prior
to LLLT being performed. Table 6 below summarizes the experimental design and
treatments for each set and phase.

Table 6: Experimental Design
Exp.

Process

G

TQ

5-FU

EGCG

LLLT

Assay

1

24, 48, 72 hours;
continuous
treatment
24, 72, 96 hours;
continuous
treatment
24, 48, 72 hours.
Phase 1:
continuous
treatment; LLLT
on day 0
Phase 2:
Continuous
treatment with
additional LLLT
treatment each
day

25 mM

16 µM

16 µM

X

X

Protein
Glut

X

X

16 µM

X

830 nm
10 J

Protein
Glut

X

16 µM

16 µM

3 µM

830 nm
10 J

Protein
Glut
NO
LDH

2

3
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Cell Collection: After the allotted times (24, 48, 72, or 96-hour period after treatments),
the supernatants from each group were collected and placed into appropriate labeled
microcentrifuge tubes and were frozen. After the supernatant was collected, 1mL of PBS
was added to the wells (6- and 24-well plates). All of the wells that contained PBS were
scraped, and the cells were collected in microcentrifuge tubes. The microcentrifuge tubes
containing the cells with PBS were placed into the centrifuge at 1500-2000 rpm for ten
minutes. The PBS was then removed from the microcentrifuge tubes down to the 0.1
mark. The pellet was left, and another 1mL of PBS was added to the tubes and
centrifuged again. The PBS was removed again down to the 0.1 mark, the 300µL of PBS
was added to the tubes containing the pellet. The tubes were vortexed to resuspend the
cells. The cells were frozen for at least one day prior to being assayed,
Biochemical Analysis: Colorimetric microtiter plate endpoint assays were performed to
determine concentrations of protein, reduced glutathione, and nitric oxide. Lactate
dehydrogenase activity was determined using spectrophotometric analysis of reduction of
NADP. Cellular protein was determined to evaluate cell viability; intracellular
glutathione was used to determine cellular stress and viability. Lactate dehydrogenase
activity and nitric oxide levels were determined in the supernatants for cell toxicity and
damage. The microtiter plates were analyzed using a Spectra plate reader to determine
concentration using the Magellan curve fit software.
Protein Assay: The initial step in the BCA protein assay process involved making the
standard solution. Eight microcentrifuge tubes were used for the standard. Albumin
Standard Ampule (500 µl, 2mg/mL) was placed in the first tube, and then 500µL of PBS
were placed in all eight tubes. A serial dilution was done, where 500µL were taken out
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of each consecutive tube and placed into the next one, but not in tube eight. These
standard solutions (25µL) were added into the first two columns of the 96-well plate
followed by 25µL of cells into the remaining wells. The working reagent was determined
by multiplying the number of wells with standards and cells by 0.2mL, which is equal to
the total working reagent (WR). The equation, 1/50=X/total amount of WR gave the
amount of reagent B when solved for X. By subtracting the amount of regent B from the
total WR, the amount of reagent A was calculated. After 200 µL of the WR was added to
all the standards and cells, the cell plate was incubated (37˚C) for 30 minutes, covered.
After the incubation period, the plate was read using the Magellan software. The
parameters: 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625, and 0 were used to compare
the standards. Wavelength (540 nm) was used for protein assay analysis.
Glutathione Assay: The initial steps in the glutathione assay were to prepare fresh
reagents. The chemicals used in the preparation included NADPH, DNTB, GSH 1, and
2, phosphate buffer, EDTA, and reductase. The standards are made by taking eight glass
test tubes and placing 100µL of GSH 2 into tubes 1 and 2, then adding 100µL of distilled
water into tubes 2-8, then doing a serial dilution, where 100µL was taken out of each
consecutive tube starting from tube two and ending at tube seven. Each standard (50 µL)
was added into the 96-well plate, then 50µL of the cells were also added into the plate.
Depending on how many samples being tested, the mixed reagent that was prepared
initially was added to the standard and cell samples (100µL). The ratio of the amount of
chemicals to use to make the mixed reagent: 1 to 1 to 1.15 (DNTB, NADPH, EDTA +
Buffer). After the mixed reagent was added, the plate was read using the Magellan
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software. After this initial reading, and incubation period of 10 minutes is done, then the
plate was read again using the Magellan software.
Nitric Oxide Assay: The initial step in the Nitric Oxide assay was to mix the necessary
chemicals to make reagent 1 and 2. Reagent 1 is made by weighing out 0.1 g of N-(1naphthyl) ethylenediamine dihydrochloride (NED) and dissolving in 100mL of distilled
water. Reagent 2 was made weighing out 1.0g of sulfaniladmide and dissolving in
100mL of 5% phosphoric acid. Aluminum foil was placed around the flask containing
Reagent 1 and 2 and placed in the refrigerator. The Standard solution is made by
weighing out 0.069 g of sodium nitrite and dissolving in 500mL of distilled water. Of
this solution, 1mL is then placed in 9mL of distilled water. Eight glass test tubes were
used and 300µL of the standard solution were pipetted into tubes 1 and 2. Of distilled
water, 300µL were added into tubes 2-8. A serial dilution was performed, starting with
taking out 300µL from tube 2, and then stopping at tube 7. Of the standards, 100µL were
pipetted into the 96-well plate, and 100µL of the supernatants were also added into the
96-well plate. A working reagent was then prepared using reagents 1 and 2 by mixing 1
part of Reagent 1 with one part of Reagent 2. The total amount of working reagent was
calculated, and then divided by 2 to determine the quantity of Reagent 1 and 2. Of the
working reagent, 100µL were added into the 96-well plate. The plate was incubated at
room temperature for at least 5 minutes before analysis at 492nm and 540 nm. Both
parameters use the concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.125, and 0 for the
curve fit parameters.
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Lactate Dehydrogenase (LDH) Assay: The initial step in the LDH assay was to prepare
the working reagent (mix 5 parts Buffer (R1) and 1 part Co-enzyme (R2). Of reagent,
1.0mL is pipetted into the appropriate cuvette tubes and pre-wared in incubator (37˚C) for
5 minutes. The spectrophometer was calibrated using a blank tube with water only at
340nm. Supernatant samples (50µL) were added to the cuvettes containing the reagents,
mixed, then were placed in incubator for 30 seconds. The first absorbance (A1) was read
and recording using the spectrophometer. The samples are then placed back in the
incubator for 30 minutes, and then A2 is read and recorded. The change in absorbance
((A2-A1)/30mins) multiplied by the factor 3376 yielded results in IU/L.
Statistics and Graphing: Sigmaplot 12.0 software was used for the statistical analysis
and one-way ANOVA data. The preferred comparison option for one-way ANOVA was
Dunnett’s and Tukey’s, however if this option was not available, Dunn’s method was
used to compare the variables and evaluate significant differences, etc. The SlideWrite
software was use for the graph production. Descriptive statistics was expressed as mean
+/- standard error of the mean (SEM). The data collected from the experiments was
statistically analyzed using the SigmaSTAT software. Group mean comparisons were
determined using one-way analysis of variance (ANOVA) to determine if any difference
differences existed among the groups. ANOVA used an F test to compare the mean of
multiple groups initially to determine if differences exist.
Multiple comparison testing was performed when significant differences were detected
using ANOVA. Several different types of multiple comparison procedures exist,
including Dunnett, Dunn, and Tukey. The Tukey posttest was used to determine which
differences among the group means were statistically significant.
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Results
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Protein Assay (Figures 3-5):
The effects of Genistein (G), Thymoquinone (TQ), and 5-Fluorouracil (5-FU) on
overall protein levels in FaDu cells were measured as a correlate to overall cell number
and cell viability (Figures 3-5). The IC50 doses (concentration found to inhibit cellular
replication by 50%) determined at the 72-hour time point of G, TQ, and 5-FU were 25
mM, 16 µM, and 16 µM respectively, informed by previous studies such as Williams et
al 2015 and Lin et al 2001. Cells treated with TQ displayed the greatest decrease in
protein levels as compared to the untreated control group at all time points (24-72 hours).
In particular, protein levels were significantly decreased by 68%, 76%, and 76% at 24,
48, and 72 hours respectively as compared to untreated control. 5-FU significantly
decreased protein levels, as compared to untreated control, at 48 and 72 hours by 51%
and 96%, respectively. In contrast, G did not significantly affect protein levels, as
compared to the untreated control, at any time point. As the concentrations of all drugs
were chosen based on previously calculated IC50 values, the lack of G effect was
surprising, but consistently noted.
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*

Figure 3: Average 24-hr cellular protein assay of FaDu cells treated with Genistein,
Thymoquinone, and Fluorouracil. Bar graph representing amount of cellular protein after
treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and control that contained
cells only. Dunnett’s Method was used for multiple comparisons versus the control
group. Any significant differences (p<0.05) for Dunnett’s multiple comparison
procedure of treatment group compared to the control are denoted with an asterisk (*).
Normality Test (Shapiro-Wilk)

Passed (P = 0.091)
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Figure 4: Average 48-hr cellular protein assay of FaDu cells treated with Genistein,
Thymoquinone, and Fluorouracil. Bar graph representing amount of cellular protein after
treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and control that contained
cells only. Any significant differences (p<0.05) for Dunn’s multiple comparison
procedure of treatment group compared to the control are denoted with an asterisk
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Kruskal-Wallis One Way Analysis of Variance on Ranks
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*
*

Figure 5: Average 72-hr cellular protein assay of FaDu cells treated with Genistein,
Thymoquinone, and Fluorouracil. Bar graph representing amount of cellular protein after
treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and control that contained
cells only. Any significant differences (p<0.05) for Dunn’s multiple comparison
procedure of treatment group compared to the control are denoted with an asterisk (*).

Normality Test (Shapiro-Wilk)
Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Glut Assay (Figures 6-8):
The effects of G, TQ, and 5-FU on overall glutathione (glut) levels in FaDu cells
were measured as a correlate to overall cellular damage. Figures 6-8 display glutathione
levels of cells when treated with previously determined IC50 doses of G, TQ, and 5-FU.
G significantly decreased glutathione levels, as compared to the untreated control, at 24
and 48 hours by 33% and 22%, respectively. TQ significantly increased in glutathione
levels at 48 hours by 200%, which was reversed to normal by 72 hours. 5-FU did not
significantly affect glutathione levels, as compared to the untreated control, at any time
point.
** Although G displayed significant change in glutathione levels, G was removed as a
treatment and replaced with EGCG (seen in the upcoming data) because EGCG was
shown to have more overall significant effect.
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Figure 6: Average 24-hr intracellular glutathione assay of FaDu cells treated with
Genistein, Thymoquinone, and Fluorouracil. Bar graph representing oxidative
damage/glut levels after treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and
control that contained cells only. Dunnett’s Method was used for multiple comparisons
versus the control group. Any significant differences (p<0.05) for Dunnett’s multiple
comparison procedure of treatment group compared to the control are denoted with an
asterisk (*).
Normality Test (Shapiro-Wilk)

Passed (P = 0.147)
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Figure 7: Average 48-hr intracellular glutathione assay of FaDu cells treated with
Genistein, Thymoquinone, and Fluorouracil. Bar graph representing oxidative
damage/glut levels after treated with 25mM Genistein, 16 µM TQ, and 16µM 5-FU and
control that contained cells only. Any significant differences (p<0.05) for Dunn’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*).
Normality Test (Shapiro-Wilk)
Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Figure 8: Average 72-hr intracellular glutathione assay of FaDu cells treated with
Genistein, Thymoquinone, and Fluorouracil. Bar graph representing oxidative
damage/glut levels after treated with 25mM Genistein, 16 µM TQ, and 16µM 5-FU and
control that contained cells only. Any significant differences (p<0.05) multiple
comparison procedure of treatment group compared to the control are denoted with an
asterisk (*).
The differences in the median values among the treatment groups are not great enough to
exclude the possibility that the difference is due to random sampling variability; there is
not a statistically significant difference (P = 0.289)
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)
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Protein Assay Phase 1 (Figures 9-11; 12):
The effects of TQ, EGCG, and 5-FU on overall protein levels in FaDu cells were
measured again, as was 3 µM of EGCG, the IC50 dose as reported in Williams et al 2015
(Figures 9-11). TQ, EGCG, and 5-FU, as compared to the untreated control, did not
significantly affect protein levels at any time point. These results are not consistent with
previous literature or with the results found in Figures 3-5, where TQ displayed
significant decrease at all time points.
The effects of each treatment in combination with laser on overall protein levels
in FaDu cells were also measured (Figures 9-11). The literature-based IC50
concentrations for each treatment were used to treat the cells. LLLT alone significantly
increased protein levels, as compared to the untreated control, at 48 hours by 74%. TQ +
laser significantly increased protein levels, as compared to the untreated control, at 48
hours by 20%, and significantly decreased protein levels, as compared to the untreated
control at 48 hours by 68%. TQ + laser also significantly decreased protein levels, as
compared to LLLT, at 72 hours by 63%. All other treatments did not significantly affect
protein levels when compared to the untreated control or LLLT alone.
An additional analysis evaluating the effects of 5-FU and 5-FU + laser on protein
levels was performed to investigate what happens to protein levels at 96 hours (Figure
12). 5-FU + laser significantly decreased protein levels, as compared to LLLT alone, at
24 hours by 44%. No other significant differences were observed. The purpose of
investigating just 5-FU at 96 hours is because we wanted to test the effects of this drug
that is actually used in treating laryngeal and hypopharyngeal carcinomas and see the
prolonged effects.
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Figure 9: 24-hr Phase 1 cellular protein assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing amount of cellular protein after treated with 10 joules (1.05J/cm2)
of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the
treatments with laser, and control that contained cells only. Any significant differences
(p<0.05) for multiple comparison procedure of treatment group compared to the control
are denoted with an asterisk (*).
The differences in the mean values among the treatment groups are not great enough to
exclude the possibility that the difference is due to random sampling variability; there is
not a statistically significant difference (P = 0.079).
Normality Test (Shapiro-Wilk)

Passed (P = 0.826)

42

*

Figure 10: 48-Hr Phase 1 cellular protein assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing amount of cellular protein after treated with
10 joules (1.05J/cm2) of 830 nm laser 3µM EGCG, 16µM TQ, and16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Kruskal-Wallis One Way Analysis of Variance on Ranks

43

*

%

Figure 11: 72-Hr Phase 1 cellular protein assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing amount of cellular protein after treated with
10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Any
significant differences (p<0.05) for Dunn’s multiple comparison procedure of treatment
group compared to the control are denoted with an asterisk (*). Any significant
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment grouped
compared to Control + Laser is denoted with a percent sign (%).
Normality Test (Shapiro-Wilk)

Passed (P = 0.522)

Kruskal-Wallis One Way Analysis of Variance on Ranks
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Figure 12: Average 24-72-96-hr cellular protein assay of FaDu cells treated with Laser,
fluorouracil, and fluorouracil plus laser. Bar graph representing amount of cellular
protein after treated with 10 joules (1.05J/cm2) of 830 nm laser, 16µM 5-FU, a
combination of these two treatments, and control that contained cells only. Any
significant differences (p<0.05) for Dunn’s multiple comparison procedure of treatment
group compared to the control are denoted with an asterisk (*).
72hrs/96hrs : The differences in the median values among the treatment groups are not
great enough to exclude the possibility that the difference is due to random sampling
variability; there is not a statistically significant difference (P = 0.352), (P=.396)
respectively
Normality Test (Shapiro-Wilk)

Failed (P < 0.050)

Kruskal-Wallis One Way Analysis of Variance on Ranks
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Glut Assay (Figures 13-15; 16):
The effects of TQ, EGCG, and 5-FU, at the same previously discussed
concentrations, on overall glutathione levels in FaDu cells were measured as a correlate
to overall cellular damage (Figures 13-15). 5-FU significantly increased glutathione
levels, as compared to the untreated control, at 48 hours by 38%. The other treatments
did not significantly affect glutathione levels at any time point.
The effects of each treatment in combination with laser on glutathione levels in
FaDu cells were also measured (Figures 13-15). The IC50 concentrations for each
treatment were still used to treat cells. LLLT alone significantly increased glutathione
levels, as compared to the untreated control, at 48 hours by 20%. TQ + laser significantly
decreased glutathione levels, as compared to LLLT alone, at 24 hours by 27%. 5-FU +
laser significantly increased glutathione levels, as compared to the untreated control, at
48 hours by 41%. The other treatments did not significantly affect glutathione levels at
any time point.
An additional analysis evaluating the effects of 5-FU and 5-FU + laser on
glutathione levels was performed to investigate what happens to protein levels at 96
hours in Figure 16. There are no significant differences in any time point.
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Figure 13: 24-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing oxidative damage/glut levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used to for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
Control + Laser is denoted with a percent sign (%).

Normality Test (Shapiro-Wilk) Passed (P = 0.229)
Equal Variance Test: Passed (P = 0.910)
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Figure 14: 48-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing oxidative damage/glut levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
Normality Test (Shapiro-Wilk) Passed (P = 0.543)
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Figure 15: 72-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing oxidative damage/glut levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunn’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
Normality Test (Shapiro-Wilk) Passed (P = 0.624)
Equal Variance Test: Failed (P < 0.050)
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Figure 16: Average 24-72-96-hr intracellular glutathione assay of FaDu cells treated with
treated with Laser, fluorouracil, and fluorouracil plus laser. Bar graph representing
oxidative damage/glut levels after treated with 10 joules (1.05J/cm2) of 830 nm laser,
16µM 5-FU, a combination of these two treatments with laser, and control that contained
cells only. Any significant differences (p<0.05) for multiple comparison procedure of
treatment group compared to the control are denoted with an asterisk (*).
24 ,72hr,96 : The differences in the median values among the treatment groups are not
great enough to exclude the possibility that the difference is due to random sampling
variability; there is not a statistically significant difference (P = 0.098), (P = 0.261), (P =
0.136).
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NO Assay Phase 1 (Figures 17-19):
The effects of TQ, EGCG, and 5-FU on overall nitric oxide (NO) levels in FaDu
cells were measured as a correlate to overall cellular stress (Figures 17-19). EGCG
displayed the greatest increase in NO levels, as compared to the untreated control, at all
time points (24-72 hours). In particular, NO levels were significantly increased by 180%,
186%, and 556% at 24, 48, and 72 hours, respectively as compared to the untreated
control. The other treatments did not show any significant differences at any time
interval.
The effects of each treatment in combination with laser on NO in FaDu cells were
also measured (Figures 17-19). EGCG + laser significantly increased NO levels, as
compared to the untreated control, at 48 and 72 hours by 223% and 620%, respectively.
EGCG + laser also significantly increased NO levels, as compared to LLLT alone, at 48
and 72 hours by 600% and 603% respectively. TQ + laser significantly increased nitric
oxide levels, as compared to the untreated control and LLLT alone, at 72 hours by 441%
and 407%, respectively. The other treatments did not display any significant differences
at any time intervals.
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Figure 17: 24-Hr Phase 1 nitric oxide assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm2) of 830
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with
laser, and control that contained cells only. Dunn’s Method was used for multiple
comparisons versus the control group. Any significant differences (p<0.05) for Dunn’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*).

Normality Test (Shapiro-Wilk) Failed (P < 0.050)

52

*

%

*

#

Figure 18: 48-Hr Phase 1 nitric oxide assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm2) of 830
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with
laser, and control that contained cells only. Dunnett’s Method was used for multiple
comparisons versus the control group. Any significant differences (p<0.05) for Dunnett’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*). An All Pairwise Multiple Comparison Procedure was done using a
Tukey Test, and any significant differences (p<0.05) for Tukey multiple comparison
procedure of treatment group compared to Control + Laser is denoted with a percent sign
(%).

Normality Test (Shapiro-Wilk) Failed (P < 0.050)
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Figure 19: 72-Hr Phase 1 nitric oxide assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm2) of 830
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with
laser, and control that contained cells only. Dunn’s Method was used for multiple
comparisons versus the control group. Any significant differences (p<0.05) for Dunn’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*). Treatment groups compared to control + laser is denoted with a
percent sign (%).
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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LDH Assay Phase 1 (Figures 20-22):
The effects of TQ, EGCG, and 5-FU on overall lactate dehydrogenase (LDH)
levels in FaDu cells were measured as a correlate to overall cellular damage and toxicity
(Figures 20-22). EGCG displayed the greatest increase in LDH levels, as compared to
the untreated control, at all time points. Specifically, LDH levels significantly increased
by 600%, 900%, and 950% at 24, 48, and 72 hours, respectively. 5-FU significantly
increased LDH levels, as compared to the untreated control, at 48 and 72 hours by 150%
and 350%, respectively.
The effects of each treatment in combination with laser on LDH levels in FaDu
cells were also measured (Figures 20-22). EGCG + laser significantly increased LDH
levels, as compared to the untreated control, at 24, 48 and 72 hours by 725% and 650%,
and 262%, respectively. EGCG + Laser also significantly increased LDH levels, as
compared to LLLT alone, at 24, 48 and 72 hours by 726% and 262%, and 775%,
respectively. 5-FU + laser significantly increased LDH levels, as compared to the
untreated control, at all time intervals. Specifically, LDH levels significantly increased
by 325%, 200%, and 500% at 24, 48, and 72 hours, respectively. 5-FU + laser also
significantly increased LDH levels, as compared to LLLT alone, at all time intervals. In
particular, LDH levels significantly increased by 325%, 100%, and 500% at 24, 48, and
72 hours, respectively.
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Figure 20: 24-Hr Phase 1 lactate dehydrogenase assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing Lactate Dehydrogenase levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
Control + Laser is denoted with a percent sign (%).
Normality Test (Shapiro-Wilk) Passed (P = 0.993)
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Figure 21: 48-Hr Phase 1 lactate dehydrogenase assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing Lactate Dehydrogenase levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser 3µM EGCG, 16µM TQ, and16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
Control + Laser is denoted with a percent sign (%).
Normality Test (Shapiro-Wilk) Passed (P = 0.051)
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Figure 22: 24-Hr Phase 1 lactate dehydrogenase assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing lactate dehydrogenase levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
Control + Laser is denoted with a percent sign (%).

Normality Test (Shapiro-Wilk) Passed (P = 0.537)
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Protein Assay Phase 2 (Figures 23-25):
The effects of TQ, EGCG, and 5-FU on overall protein levels in FaDu cells were
measured as a correlate to cell number and cell viability (Figures 23-25). Phase 2 differs
from phase 1 because additional laser treatment was added each day rather than
continuous laser treatment on day 0 for phase 1. TQ, EGCG, and 5-FU did not display
any significant difference at any time point.
The effects of each treatment in combination with laser on protein levels in FaDu
cells were also measured in Figures 23-25. TQ + laser significantly decreased protein
levels, compared to control and control + laser, at 72 hours by 60% and 66%,
respectively. 5-FU + laser significantly decreased protein levels, as compared to control
+ laser, at 72 hours by 49%. The other treatments do not display any significant
differences.
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Figure 23: 24-hr Phase 2 cellular protein assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing amount of cellular protein after treated with
10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Any
significant differences (p<0.05) for multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
The differences in the median values among the treatment groups are not great enough to
exclude the possibility that the difference is due to random sampling variability; there is
not a statistically significant difference (P = 0.488)
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Figure 24: 48-hr Phase 2 cellular protein assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing amount of cellular protein after treated with
10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Any
significant differences (p<0.05) for multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
The differences in the median values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.021)
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Figure 25: 72-Hr Phase 2 cellular protein assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing amount of cellular protein after treated with
10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
Control + Laser is denoted with a percent sign (%).
Normality Test (Shapiro-Wilk) Passed (P = 0.131)
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Glut Assay Phase 2 (Figures 26-28):
The effects of TQ, EGCG, and 5-FU on overall glutathione levels in FaDu cells
were again measured as a correlate to overall cellular damage (Figures 26-28). Phase 2
consisted of laser treatment each day rather than continuous later treatment on day 0.
EGCG significantly decreases glutathione levels at 48 hours by 36%. The other
treatments did not display any significant differences.
The effects of each treatment in combination with laser on glutathione levels in
FaDu cells were also measured in Figures 26-28. The IC50 concentrations for each
treatment were still used to treat cells. There are no significant differences displayed at
any time point.
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Figure 26: 24-Hr Phase 2 intracellular glutathione assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing oxidative damage/glut levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).

Normality Test (Shapiro-Wilk) Passed (P = 0.229)
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Figure 27: 48-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing oxidative damage/glut levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
Normality Test (Shapiro-Wilk) Passed (P = 0.208)
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Figure 28: 72-Hr Phase 2 intracellular glutathione assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing oxidative damage/glut levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunn’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk

Normality Test (Shapiro-Wilk) Passed (P = 0.088)
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NO Assay Phase (Figures 29-31):
The effects of TQ, EGCG, and 5-FU on overall NO levels in FaDu cells were
measured as a correlate to overall cellular function (Figures 29-31). Phase 2 consisted of
laser treatment each day rather than continuous later treatment on day 0. EGCG
significantly increased NO levels, as compared to the untreated control, at 24, 48, and 72
hours by 690%, 300%, and 3067%, respectively. TQ significantly increased nitric oxide
levels, as compared to the untreated control, at 48 hours by 125%. The other treatments
did not display any significant differences.
The effects of each treatment in combination with laser on glutathione levels in
FaDu cells were also measured in Figures 29-31. EGCG + laser significantly increase
nitric oxide levels, as compared to the untreated control, at 24, 48, and 72 hours by 733%,
250%, and 2700%, respectively. EGCG + laser also significantly increase nitric levels,
as compared to laser alone, at 24, 48, and 72 hours by 734%, 192%, and 2233%,
respectively. The other treatments did not display any significant differences.
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Figure 29: 24-Hr Phase 2 nitric oxide assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm2) of 830
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with
laser, and control that contained cells only. Dunnett’s Method was used for multiple
comparisons versus the control group. Any significant differences (p<0.05) for Dunnett’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*). An All Pairwise Multiple Comparison Procedure was done using a
Tukey Test, and any significant differences (p<0.05) for Tukey multiple comparison
procedure of treatment group compared to Control + Laser is denoted with a percent sign
(%).
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Figure 30: 48-Hr Phase 2 nitric oxide assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm2) of 830
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with
laser, and control that contained cells only. Dunnett’s Method was used for multiple
comparisons versus the control group. Any significant differences (p<0.05) for Dunnett’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*). An All Pairwise Multiple Comparison Procedure was done using a
Tukey Test, and any significant differences (p<0.05) for Tukey multiple comparison
procedure of treatment group compared to Control + Laser is denoted with a percent sign
(%).
Normality Test (Shapiro-Wilk) Passed (P = 0.363)
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Figure 31: 72-Hr Phase 2 nitric oxide assay of FaDu cells treated with Thymoquinone,
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm2) of 830
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with
laser, and control that contained cells only. Dunn’s Method was used for multiple
comparisons versus the control group. Any significant differences (p<0.05) for Dunn’s
multiple comparison procedure of treatment group compared to the control are denoted
with an asterisk (*). Treatment group compared to Control + laser denoted with a
percent sign (%).
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Kruskal-Wallis One Way Analysis of Variance on Ranks
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LDH Assay Phase 2 (Figures 32-34):
The effects of TQ, EGCG, and 5-FU on overall LDH levels in FaDu cells were
measured as a correlate to overall cellular damage and toxicity (Figures 32-34). Phase 2
consisted of laser treatment each day rather than continuous later treatment on day 0.
EGCG significantly increase LDH levels, as compared to the untreated control, at 48 and
72 hours by 320% and 483%, respectively. The other treatments did not display any
significant differences.
The effects of each treatment in combination with laser on LDH levels in FaDu
cells were also measured (Figures 32-34). EGCG + laser significantly increase LDH
levels, as compared to untreated control, at 48 and 72 hours by 420% and 980%,
respectively. EGCG +laser also significantly LDH levels, as compared to LLLT alone, at
48 and 72 hours by 150% and 210%, respectively. 5-FU + laser significantly increased
LDH levels, as compared to untreated control, at 48 and 72 hours by 260% and 667%,
respectively. 5-FU + laser also significantly increase LDH levels, as compared to LLLT
alone, at 72 hours by 119%. The other treatments did not display any significant
differences.
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Figure 32: 24-Hr Phase 2 lactate dehydrogenase assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing lactate dehydrogenase levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunn’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*).
The differences in the mean values among the treatment groups are not great enough to
exclude the possibility that the difference is due to random sampling variability; there is
not a statistically significant difference (P = 0.655)
Normality Test (Shapiro-Wilk) Passed (P = 0.704).
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Figure 33: 48-Hr Phase 2 lactate dehydrogenase assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing lactate dehydrogenase levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
control + laser is denoted with a percent sign (%).
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Figure 34: 72-Hr Phase 2 lactate dehydrogenase assay of FaDu cells treated with
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and
Fluorouracil + Laser. Bar graph representing lactate dehydrogenase levels after treated
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a
combination of the treatments with laser, and control that contained cells only. Dunnett’s
Method was used for multiple comparisons versus the control group. Any significant
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple
Comparison Procedure was done using a Tukey Test, and any significant differences
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to
control + laser is denoted with a percent sign (%).
Normality Test (Shapiro-Wilk) Passed (P = 0.994)
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Discussion
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Based on the findings of the current study, FaDu cells treated with 3 µM EGCG
showed the greatest overall anti-cancer effect, in terms of promoting damage to FaDu
cells, especially notable with increased changes in NO and LDH, compared to the
untreated control. In the first part of the experiment, TQ consistently showed a
significant decrease in protein levels and glutathione levels; however, these effects were
not consistent and are not displayed in the other protein analyses or any other analyses
performed. This drastic change in the results could be due to the possibility that the TQ
stock used during the phase 1 and 2 experiments could have been too old, and was not as
effective as when it was during the first set of experiments. 5-FU + laser displayed
significant effects similar to EGCG when observing the LDH levels as compared to the
untreated control; however, the results were not as consistent or effective as EGCG.
Overall, the laser seems to not have any significant effects by itself or when combined
with the treatments.
Many chemotherapeutic drugs stop cells in cycling through the cell cycle. The
cell cycle is divided into four parts: G1, S, G2, and M. Cancer cells treated with the
nucleoside analog chemotherapeutic agent, 5-FU, stops division of cells in the S phase of
the cell cycle by being incorporated into RNA and DNA and halting translation,
transcription, and replication, respectively (Wilkes et al 2008). Limited and conflicting
information exists regarding natural agents, genistein and TQ. Both treatments have been
shown to stop cells in the G0-G1 phase of the cell cycle and induce apoptosis possibly by
increasing the ratio of Bax/Bcl-2 protein expression and decreasing Bcl-xL protein,
which are type of anti- or pro-apoptotic regulatory proteins depending on the amount
present in the cell (Gali-Muhtasib et al 2004; Shoieb et al 2003). Because G did not have
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a significant effect on the cells, this treatment was later exchanged for EGCG, which was
found in our lab to be effective against cancer cells, particularly hypopharyngeal
carcinoma (Williams et al 2015). EGCG also arrests cells in the G0-G1 phase of the cell
cycle by inhibiting the cyclin-dependent kinase complexes that are involved in cell cycle
control in those phases (Gupta et al 2003; Liu et al 2015). Most of these therapies and
their effects on the cell cycle have been investigated with different types of cancer cells
such as human esophageal/oral squamous cell carcinoma (Liu et al, 2015; Irimie et al,
2015), human prostate carcinoma (Gupta et al,2003), and lung cancer cells (Flores-Perez
et al, 2015). Based on these previous studies, laryngeal and hypopharyngeal carcinomas
seem like they would also be plausible cancer cell types that could be affected by the proapoptotic effects of these therapies by cell cycle arrest.
Throughout our study we noted that our findings were inconsistent, especially for
TQ. Our initial results show TQ to be effective at decreasing cell proliferation and
inducing cell damage; but significant TQ effects were not noted throughout the entirety
of the study. Notably, the time when the first set of results was done several months
earlier than the experiments including the laser was conducted. This could possibly hint
at the idea that the stock of TQ used could have been old, and the effects were not
presented accurately. Many studies have displayed TQ as being an effective, putative
treatment against different cancer cells. For example, TQ induced p53- dependent
apoptosis in human osteosarcoma cells (Roepke et al 2007), and increased apoptosis in
ID8-NGL mouse ovarian cancer cells (Wilson et al 2015). TQ was also found to
significantly inhibit proliferation in human breast adenocarcinoma cells (Dehghani et al
2015). TQ’s pro-apoptotic effects, however, are not clearly and consistently seen in this
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study. TQ likely becomes an inducer of glutathione as the cells are trying to recover and
protect cells from the protein loss and damage due to treatment. A change in glutathione
levels is indicative of toxicological responses and oxidative stress, which can lead to
apoptosis (Gokce et al 2016). Due to these inconsistencies in our results, it would be
plausible to re-evaluate the effects on TQ on FaDu cells.
EGCG was a plausible treatment option for laryngeal or hypopharyngeal cancer in
the present study. Previous studies have shown that EGCG increases apoptosis and
decreases cell proliferation in cancer cells such as lung cancer cells, human oral
squamous cell carcinoma cells, and hypopharyngeal carcinoma cells (Flores-Perez et al
2015; Lee et al 2015; Williams et al, 2015). In the current study, EGCG was found to
significantly affect nitric oxide and LDH levels, but not overall protein or glutathione
levels. The increased nitric oxide levels due to EGCG are consistent with the study by
Harpole et al (2015).

Nitric oxide has many versatile biological effects on the system,

and increased nitric oxide levels could indicate either a positive or negative response on
the system. For example, increased nitric oxide levels could lead to oncogene expression,
oxidative DNA damage, angiogenesis, and inhibition of DNA repair enzymes and/or
dysregulation of apoptosis; however, nitric oxide can also generate apoptosis/death.
This uncertainty of the meaning of the increased nitric oxide levels due to EGCG is
clarified when evaluating the LDH levels. LDH is used to evaluate the presence of
damage to, and toxicity of, cells. The LDH levels were significantly increased by EGCG,
indicating the FaDu cells were being damaged. These results align with studies showing
that EGCG displays pro-apoptotic effects on cancer cells (Lee et al, 2015; Liu et al,
2015).
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Low level light therapy (LLLT) has been controversial in the literature in regards
to treating different types of cancer. LLLT induced cell death in a human colon
carcinoma cell line (HCT 116) by increasing intracellular reactive oxygen species (ROS)
concentrations, which were induced by mitochondrial damage (Saenko et al 2016). The
photons in LLLT absorb cytochrome-C oxidase, which is part of the mitochondrial chain.
This reaction leads to increased electron transport, respiration, oxygen consumption, and
ATP production (Tanupriya et al 2014). Studies of LLLT by Kreisler et al (2002 and
2003) showed enhanced cell proliferation, including on human laryngeal carcinoma in
vitro, from 1.96-7.84 J/cm2 with LLLT of wavelength 809 nm. This is in contrast to some
of the results of this study, where LLLT did not consistently show significant increase in
overall protein levels, although in one set of cells from one duplicate experiment at 48
hours, the protein assay did show a significant increase in protein levels, which aligned
with the studies by Kreisler et al. Pinheiro et al (2002) reported that LLLT with 635 nm
wavelength did not significantly stimulate laryngeal carcinoma cells, whereas, the LLLT
with a wavelength of 670 nm wavelength significantly stimulated these cancer cells
compared to the control, with every irradiation being 0.04-0.48J/cm2. Other researchers,
such as Werneck et al (2005) who used LLLT with wavelengths of 685 nm and 830 nm
significantly increased the proliferation of laryngeal carcinoma cells. Notably, the results
of Renno et al (2007), reported an increase in normal osteoblast cells and reduction in
osteosarcoma cells after treating with LLLT at 830 nm and a total energy impact of 10
J/cm2. In our present study, we impacted a total energy of 10 J, which is equivalent to
1.05 J/cm2 into each well using LLLT of 830 nm wavelength. The conflicting results one
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may observe in the literature, and between previous report and the present study, may be
due to time of exposure, treatment and wavelength or parameters used.
In the present study, we wanted to combine LLLT with the treatments, TQ,
EGCG, and 5-FU, in order to possibly find a combination that would be most effective.
Most combinations of the drug treatments with LLLT did not highlight a therapeutic
benefit. However, TQ + laser showed significant decrease in protein levels from one
duplicate experiment at 48 and 72 hours, but these results may not be enough to make
any conclusive analysis about TQ + laser. Notably, 5-FU + laser significantly increased
LDH levels, which is not seen in 5-FU alone, which could possibly mean that LLLT aids
in cellular damage and toxicity. LLLT combined with EGCG did show a significant
difference showing similar results with the treatment of EGCG alone, but the
combination did not prove to be more effective than the treatments alone. In conclusion,
our results consistently demonstrate reduction in hypopharyngeal tumor cells following
treatment EGCG alone and when combined with laser therapy, but that there was no
overall additive effect. TQ and 5-FU results were inconsistent, and this study requires
further investigation in order to clarify consistent findings and further treatments to test
in-vivo.
Currently, researchers are trying to find out if certain drugs, vitamins, or other
supplements can help prevent precancerous lesions from developing into laryngeal and
hypopharyngeal carcinomas. Surgery techniques are also being refined in order to
effectively take out laryngeal and hypopharyngeal tumors. More chemotherapeutic drugs
are also being tested for these types of cancer (American Cancer Society, 2016). In this
present study, there were many inconsistent findings that were contrary to previous
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studies. Although treatment with EGCG seems to be the most effective treatment
compared to the others, there could be possible combinations of these drugs that could
prove to be even more effective. For future studies, it would be plausible to investigate
the effects of EGCG in combination with 5-FU and TQ, and also with different
wavelengths of LLLT other than 830 nm.
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